Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA5108 Ocular Implants in Open-angle Glaucoma or Ocular Hypertension
NCT06964191Phase 2Active, not recruiting
- Sponsor
- PolyActiva
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PA5108 Latanoprost FA SR Ocular Implant in open-angle glaucoma (OAG), ocular hypertension, sponsored by PolyActiva. Started May 2025; status: active, not recruiting.
02
Drugs
PA5108 Latanoprost FA SR Ocular Implant
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06964191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964191.